• Price (USD)223.25
  • Today's Change-0.40 / -0.18%
  • Shares traded399.37k
  • 1 Year change-14.46%
  • Beta0.8265
Data delayed at least 15 minutes, as of Jan 19 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Masimo Corporation is a global medical technology company that develops, manufactures, and markets noninvasive technologies and hospital automation solutions. Its patient monitoring solution that incorporates a monitor or circuit board, single-patient use or reusable sensors, software and cables. The Company’s main products include Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include noninvasive monitoring of blood constituents with an optical signature, optical regional oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring, exhaled gas monitoring, nasal high flow ventilation, minimally invasive neuromodulation technology for pain. It sells its products hospitals, emergency medical service (EMS) providers, home care providers, long-term care facilities, physician offices, veterinarians and consumers through direct sales force, distributors and original equipment manufacturers (OEM) partners.

  • Revenue in USD (TTM)1.21bn
  • Net income in USD232.06m
  • Incorporated1996
  • Employees1.60k
  • Location
    Masimo Corp52 DiscoveryIRVINE 92618-3105United StatesUSA
  • Phone+1 (949) 297-7000
  • Fax+1 (949) 297-7499
  • Websitehttps://www.masimo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Coherent, Inc.1.49bn-106.75m6.31bn5.09k--7.23--4.24-4.40-4.4060.6135.380.80052.216.33292,520.80-5.740.1559-6.960.185339.0639.65-7.180.20122.0611.720.33850.0021.0311.6574.22--10.85--
Globus Medical Inc941.53m187.04m7.18bn2.20k38.924.1827.957.631.821.829.1516.940.54551.026.22427,966.4010.8410.4411.5811.3474.6975.8619.8718.266.09--
Envista Holdings Corp2.79bn350.40m7.26bn12.40k22.821.8415.272.601.972.0415.7024.410.42364.588.29224,911.305.32--6.25--56.3156.0312.567.571.186.980.24980.00-17.07-3.57-84.70-34.47----
Tandem Diabetes Care Inc660.87m21.76m7.38bn1.50k339.0818.93207.9511.170.34280.342810.366.140.86774.519.47440,578.702.86-33.593.35-45.2153.4249.503.29-31.525.764.210.419--37.6846.93-38.90--41.15--
Penumbra Inc710.48m33.57m8.36bn3.30k249.5311.87189.9611.760.89660.896619.0618.840.79671.186.10215,296.103.352.893.813.3062.5364.694.213.373.53--0.03980.002.3824.67-132.40--35.23--
Henry Schein, Inc.12.24bn625.92m10.58bn19.00k17.353.0712.900.86444.394.4085.8924.851.515.358.27644,011.807.696.2713.6611.2429.0329.595.104.690.924835.450.1410.001.34-0.9797-42.51-3.41-7.39--
DENTSPLY SIRONA Inc4.25bn417.50m11.62bn15.00k28.002.2715.172.741.901.9019.3023.430.46693.746.17283,020.004.59-4.205.26-4.6755.0252.789.84-10.131.1310.850.2883---17.064.56-131.57--3.862.34
Masimo Corporation1.21bn232.06m12.35bn1.60k55.688.4146.3210.244.024.0220.8926.590.69352.097.10754,143.1013.3421.0715.3724.9964.6766.3419.2325.774.10--0.000.0021.9612.6622.4723.607.93--
ABIOMED, Inc.973.64m149.15m13.30bn1.73k89.909.6175.5913.663.253.2521.3230.430.68132.0811.42564,426.1010.4419.1211.3021.3781.9082.5015.3224.976.89--
Teleflex Incorporated2.76bn434.26m15.26bn14.00k35.574.1722.775.539.169.1458.1978.090.40412.476.98197,059.106.365.316.885.8654.8654.9315.7412.891.888.040.359120.64-2.246.99-27.317.318.100.00
Insulet Corporation1.04bn-29.50m16.15bn1.90k--32.41417.1915.57-0.4531-0.453115.467.220.55921.7610.39545,894.80-1.59-0.7253-1.78-0.828767.4963.25-2.84-1.064.581.170.7209--22.5127.93-41.38--73.44--
Hologic, Inc.5.63bn1.87bn17.45bn6.71k9.634.177.673.107.217.2121.7516.630.6994.105.71840,014.9023.208.3327.6010.1767.4058.3533.2016.162.0129.010.41980.0049.1414.7467.8241.4210.56--
Data as of Jan 19 2022. Currency figures normalised to Masimo Corp's reporting currency: US Dollar USD

Institutional shareholders

38.41%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20214.57m8.27%
The Vanguard Group, Inc.as of 30 Sep 20214.56m8.25%
BlackRock Advisors LLCas of 30 Sep 20212.73m4.95%
Ownership Capital BVas of 30 Sep 20212.01m3.64%
Fidelity Management & Research Co. LLCas of 30 Sep 20211.88m3.40%
SSgA Funds Management, Inc.as of 30 Sep 20211.69m3.06%
Champlain Investment Partners LLCas of 30 Sep 20211.09m1.97%
Invesco Advisers, Inc.as of 30 Sep 2021973.83k1.76%
BlackRock Investment Management (UK) Ltd.as of 30 Sep 2021863.32k1.56%
Massachusetts Financial Services Co.as of 30 Sep 2021845.74k1.53%
More ▼
Data from 30 Sep 2021 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.